Cellectis (CLLS) Non-Current Deferred Tax Liability (2023 - 2024)

Name: Cellectis (CLLS) Non-Current Deferred Tax Liability (2023 - 2024) | Business Quant
Creator: Business Quant

Cellectis (CLLS) posted Non-Current Deferred Tax Liability of $118000.0 for Q3 2024, down 25.32% on a QoQ basis from $158000.0 in Q4 2023.

Cellectis (CLLS) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $118000.0 in Q3 2024.

In Q3 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $118000.0; the TTM figure through Sep 2024 stood at $118000.0 (changed N/A YoY), while the FY2023 annual figure was $158000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability eased to $118000.0 in Q3 2024, from $158000.0 in the prior quarter.
Across five years, Non-Current Deferred Tax Liability topped out at $158000.0 in Q4 2023 and bottomed at $118000.0 in Q3 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	1,216,509.61 Bn	1,216,509.61 Bn	-
2	Alterity Therapeutics	764,224.41 Bn	764,224.38 Bn	-
3	Legend Biotech	2,716.00 Bn	2,715.71 Bn	242.10 Mn
4	Nanobiotix	2,248.83 Bn	2,248.77 Bn	-
5	Akari Therapeutics	1,951.18 Bn	1,951.17 Bn	-
6	Vertex Pharmaceuticals	113.69 Bn	106.44 Bn	2.59 Bn
7	Evaxion A	64.16 Bn	64.14 Bn	-
8	Regeneron Pharmaceuticals	63.94 Bn	55.18 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	40.13 Bn	37.12 Bn	959.66 Mn
10	Cellectis	20.83 Bn	20.62 Bn	-

Download Data 🔒